2. Academic Validation
  3. Sanggenol F exerts anti-diabetic effects via promoting adipocyte differentiation and modifying adipokines expression

Sanggenol F exerts anti-diabetic effects via promoting adipocyte differentiation and modifying adipokines expression

  • Endocrine. 2017 Apr;56(1):73-81. doi: 10.1007/s12020-016-1203-3.
Jing-Jie Zhu 1 2,  Jun-Shang Huang 1 2,  Ting Wang 1,  Jun Ji 3,  Ai-Jun Hou 4,  He-Yao Wang 5
Affiliations

Affiliations

  • 1 Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 201203, China.
  • 2 University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing, 100049, China.
  • 3 Department of Pharmacognosy, School of Pharmacy, Fudan University, 826 Zhang Heng Road, Shanghai, 201203, China.
  • 4 Department of Pharmacognosy, School of Pharmacy, Fudan University, 826 Zhang Heng Road, Shanghai, 201203, China. ajhou@shmu.edu.cn.
  • 5 Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 201203, China. hywang@simm.ac.cn.
PMID: 28004237 DOI: 10.1007/s12020-016-1203-3
Abstract

Adipose tissue is not only a lipid storage site, but also a well-known endocrine organ. Dysfunction of adipose tissue is associated with irregular lipid metabolism, ectopic lipid accumulation and Insulin resistance. It is proposed that modulating on adipose tissue is a reasonable way to ameliorate glucose and lipid metabolism. (±)-sanggenol F (SGF, purity >98.5%) was synthesized as a racemic mixture of natural (+)-sanggenol F. In this study, SGF was found to promote adipocyte differentiation, enhance Insulin sensitivity, and upregulate beneficial adipokines expression in 3T3-L1 cells. Furthermore, in vivo study showed that treatment with SGF for 4 weeks improved glucose metabolism, by decreasing fasting blood glucose and enhancing Insulin sensitivity. It also improved lipid metabolism, with reduced serum lipid level and ameliorated hepatic steatosis in db/db mice. During the process of target finding, we found that SGF had multiple activities of protein tyrosine Phosphatase 1B inhibition, Peroxisome Proliferator-activated Receptor γ and Peroxisome Proliferator-activated Receptor α agonism. These results showed the potential of SGF as a candidate for the therapy of type 2 diabetes.

Keywords

Adipogenesis; Adipokine; PPARγ; PTP1B; Sanggenol F; Type 2 diabetes.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z